Cancer Research UK Science and Innovation’s Post

I am so incredibly honored to have contributed to this paper with Rowan Beck, PhD, Erin Beck, Sam Pathak, and so many others showcasing the National Cancer Institute (NCI) Cancer Research Data Commons Cloud Resources, of which have been a part of for the past 2 and a half years. A direct quote from the announcement shared below, "In just ten years, the CRDC has proven itself as an important source to the broad cancer research community. This manuscript series in Cancer Research highlights how far we have come in a relatively short time, and points to the opportunities ahead as we continue to serve a foundational role in NCI's cancer data ecosystem." —Tanja Davidsen, Chief, CBIIT Data Ecosystems Branch I hope my network enjoys reading about the CRDC and utilizes the amazing data, tools, and community. #cancerresearch #bioinformatics https://lnkd.in/etJ-tFwG

Change Our Future has committed to funding numerous American Association for Cancer Research (AACR) programs and initiatives to develop the next generation of cancer researchers. These programs include the AACR Special Program for High School Students and the AACR Minority Scholar in Cancer Research Travel Awards. At the 2023 AACR Minority Scholars in Cancer Research Conference, COF supported 3 scholars: - Alexis E. Carey, a PhD candidate at The Johns Hopkins University in Baltimore, Maryland. Carey is currently focused on improving outcomes for elderly patients with melanoma by studying age-specific immune responses to melanoma and the impact of aged bone marrow on anti-tumor response. - Afia P. Ohemeng, MD, a PhD candidate at Florida A&M University in Tallahassee, Florida. Ohemeng is working toward integrating her clinical and laboratory skills to build a career in translational research. - Dominique V. Parker, a PhD candidate at Vanderbilt University in Nashville, Tennessee. Parker’s current research explores how the expression of EphA2 in breast cancer impacts different cell types involved in bone homeostasis. #ChangeOurFuture #AACRPrograms #CancerResearch #MinorityScholars #PhDResearch #MedicalResearch

Sally is about to hit two HUGE milestones! On 18th May, she’ll be taking on her 20th MoonWalk London and in 2025, she’ll celebrate a remarkable 40 years working in breast cancer research. The highlight of Sally’s career was being part of the team which discovered the altered BRCA2 gene in 1995 – people who carry the gene are more likely to be diagnosed with breast or ovarian cancer. “Twenty MoonWalks – and almost forty years working in breast cancer research. I honestly don’t know where the time has gone! I started off as a hands-on researcher, but more recently, my role has been as the Laboratory Manager for the Breast Cancer Now Toby Robins Research Centre, at The Institute of Cancer Research in London. I manage the labs and ensure that the bench scientists have everything they need to do their research. I basically make sure that the researchers don’t get bogged down with the housework of science. Having been a scientist myself, I know what they need and what’s important. When I signed up for my first MoonWalk London in 2001, I was already an experienced cancer researcher. I always have such fun taking part and I particularly enjoyed the years when I walked with my two children, who were still in their teens at the time. I was so proud of them both. The night of The MoonWalk is always quite emotional for me, particularly when I cross the line at the end. Even now, I still feel really moved, but at the same time I feel a huge buzz of achievement, which is why I keep coming back. ” Click the link below to read Sally’s story in full… https://lnkd.in/eQsp-wqD #breastcancerawareness #breastcancerwarrior #inspirational #raiseawareness #research #scientist #blog #story #walkers #supporters

Cancer is a leading cause of death worldwide, causing at least 10 million deaths yearly, or nearly one in six. Cancer research plays a vital role in helping to save lives, which is why we are deeply committed to supporting research to help prevent cancer and catch it early. Our team recently celebrated the milestone of being cited more than 1,000 times across Nature, Frontiers, Cell, and other scientific publications. 75% of these publications are devoted to cancer research, and we're incredibly gratified to see scientists worldwide choosing Akoya to make a lasting impact on people's lives. https://bit.ly/45wIYzg On this #WorldCancerResearchDay, we sincerely thank the incredible, emerging cancer researchers who have made life-changing achievements to make treatment more effective. The image featured below is courtesy of our customer and pioneer of spatial biology, Dr. Arutha Kulasinghe's cellular atlas of skin cancer; it shows the epidermal layer in blue and glands near the surface. Dr. Kulasinghe's tumor mapping approach, the world's most in-depth cellular atlas, allows scientists to identify cellular structures and areas of therapy resistance for the first time. #cancerresearch #spatialbiology #spatialproteomics #cancerimmunotherapy #immunooncology #AkoyaInAction

Peel back the veil on the enigmatic world of cancer research with The Unseen Side of Cancer Research: Unraveling the Mysteries and Myths. This article explores the complex and intricate nature of cancer research, debunking common myths about cancer, and highlighting the significant advancements made in the field. With a focus on the human narratives behind the research, it also explores the future of cancer research, which holds immense promise with advancements in precision medicine, genomics, immunotherapy, and the integration of artificial intelligence and machine learning.

We’re excited to announce Flicker of Hope’s $500,000 partnership with The Brain Cancer Centre. Flicker Of Hope Foundation have been a significant supporter of our research superstar Dr Jim Whittle & his WEHI (Walter and Eliza Hall Institute of Medical Research) team’s research focused on Neurofibromatosis. This project is incredibly special as it recognises the connection of Elizabeth Petropoulos and her battle with this disease. It will be known as “Elizabeth’s Legacy - Deciphering the Molecular Mosaic of NF2” and will be a flagship program of The Brain Cancer Centre, connecting the current resources of our other funded programs to grow our understanding of this devastating disease. NF is a genetic disorder that causes tumours, blindness and learning difficulties. With limited treatments and no cure, more research is crucial to bring hope to families impacted by NF. We’re so excited to welcome this new collaboration to The Brain Cancer Centre family. We know that collaboration is key to making progress quicker & building a brighter future for brain tumour and NF patients and their families. This significant contribution enables us to bring the best and brightest minds together, with a laser focus on solving the puzzle created by brain and other tumours. We can’t wait to see what exciting progress this collaboration will make to patients & their families. Many minds. One focus #thebraincancercentre #flickerofhopefoundation #Neurofibromatosis #manymindsonefocus

In the rapidly evolving world of cancer research, a new era is dawning - one that leverages the power of APIs from arXiv and INPIRE-HEP to transform affiliation-based research. Despite the current limitations of arXiv's API for affiliation searches, the resilient spirit of researchers has led to the ingenious workaround of querying the author field. This workaround strategically sidesteps the limitations and continues to empower research efforts. Equally thrilling is the roadmap for arXiv's API, as the development team has hinted at future enhancements, including the addition of affiliation as an indexed search field. This advancement will significantly boost the API's capabilities, thereby revolutionizing how researchers navigate the complex landscape of cancer research. Meanwhile, the INPIRE-HEP API already facilitates refined, affiliation-based searches. These tools, with their advanced search capabilities, are more than just a technological innovation; they are powerful allies in humanity's fight against cancer. As the features improve, the ripple effect will be profound. The ability to efficiently identify relevant publications from specific institutions or authors will empower researchers, facilitating collaboration, and accelerating the pace of breakthroughs. This is not just about making research more efficient, but about enhancing our collective ability to wage war on cancer. We stand on the brink of a new era of affiliation-based research, a testament to our relentless pursuit of knowledge and our enduring battle against cancer. Read more about this exciting development in our latest blog post - 'Unleashing the Power of ArXiv and INPIRE-HEP APIs: A New Era for Affiliation-Based Research in Cancer Studies.' #CancerResearch #API #arXiv #INPIREHEP #AffiliationResearch #Innovation #Collaboration #FightAgainstCancer Read more on our blog: https://lnkd.in/dM8c9db5

🔬In the fast-paced landscape of cancer research, navigating complex databases like arXiv and INPIRE-HEP is vital. Issues in searching based on affiliations and ORCID in arXiv API have highlighted the need for enhanced search capabilities - a void INPIRE-HEP is striving to fill. arXiv API is an indispensable tool for researchers, yet its search limitations, particularly with affiliations and ORCID, present significant challenges. The affiliation field is not indexed for search and there's no specific query format for searching based on ORCID. Enter INPIRE-HEP - serving as a beacon of hope for affiliation searches, hosting high-energy physics literature, and offering the unique benefit of searching based on affiliations while we await improvements to arXiv API. In fields like cancer research, where collaboration and access to comprehensive information are paramount, the value of effective ORCID searches can't be overstated. Despite the arXiv API limitations, its future enhancements and the current capabilities of INPIRE-HEP facilitate efficient navigation through cancer research's complex terrain. The roadmap for arXiv API 2020 indicates plans to enhance its capabilities, potentially including the long-awaited ability to search based on affiliations and ORCID. This evolution is a beacon of hope for the scientific community. Cancer research necessitates accurate information and collaboration. Effective Affiliation and ORCID searches provide invaluable insights into the latest advancements. The anticipated advancements in arXiv API, coupled with INPIRE-HEP's utility, promise to enrich the scientific landscape and expedite breakthroughs in fields as critical as cancer research. Let's rally behind the promise of these advancements and look forward to a future where the mysteries of cancer are systematically unraveled. #CancerResearch #arXivAPI #INPIRE-HEP #AffiliationSearches #ORCIDSearches #Science #Research #Collaboration Read more on our blog: https://lnkd.in/eUiPgzpE

Publication alert: My paper titled " Embracing Subjectivity: An autoethnographic account of the lived experience of a Nigerian Cancer Care ethnonursing researcher" has been accepted for publication in CANCER NURSING-An International Journal for Cancer Care Research. The editor-in Chief described it as " excellent and compelling". So, I wrote this manuscript in the form of an autoethnographic account of my experience while researching the context of cancer and cancer care in Nigeria. This article advances the conversation on conducting cancer-based ethnonursing research among under-reported populations by examining the challenges and lessons learned from my cancer care ethnonursing journey. Through this study, I have discovered insights and revealed blind spots or the ‘unknown unknowns’ in cancer care in Nigeria.  This research has been a life-altering experience for me. Lessons learned will shape my future endeavors, inspiring me to be a better cancer care researcher.  

Peel back the veil on the enigmatic world of cancer research with The Unseen Side of Cancer Research: Unraveling the Mysteries and Myths. This article explores the complex and intricate nature of cancer research, debunking common myths about cancer, and highlighting the significant advancements made in the field. With a focus on the human narratives behind the research, it also explores the future of cancer research, which holds immense promise with advancements in precision medicine, genomics, immunotherapy, and the integration of artificial intelligence and machine learning.